The primary drivers driving the market's growth include the rising incidence of respiratory infections, the growing newborn population base, the rising need for in-vitro diagnostics, and the rising demand for point-of-care facilities. According to the World Health Organization (WHO), pneumonia caused 16 percent of all fatalities in children under the age of five in 2015, with 9, 20,136 children dying.
A mild Respiratory Syncytial Virus (RSV) affects young children's upper respiratory systems. Coughing, sore throats, wheezing, and runny noses frequently characterize RSV. Rapid protein detection relies heavily on antigen-antibody reactions. Antibodies can be exceedingly specific, binding to only a small portion of an antigen, and can distinguish between very similar antigens. They detect proteins based on both their structure and content. Due to their weakened immune systems, older persons are more susceptible than young adults to significant consequences from RSV. The primary diagnostic procedure is a physical examination by the physician. In extreme cases, the doctor does tests, including molecular diagnostics for virus identification, serology tests, and quick antigen detection tests.
Initial signs of respiratory syncytial viruses (RVs) include a moderate cold with symptoms such as congestion, a runny nose, coughing, sore throat, and fever. Young newborns may exhibit signs of exhaustion, irritability, and respiratory issues. Under typical circumstances, these symptoms subside after a few days. The rising incidence of respiratory syncytial virus infections worldwide, increased investments, technical developments, product approvals and introductions, government efforts, and other important strategies the leading market players take are the factors driving the studied industry's growth. Advanced methods like bio- and nanotechnology (PCR) are helping to develop current RSV detection technologies, such as western blot, enzyme-linked immunosorbent test (ELISA), direct immunofluorescence, and real-time polymerase chain reaction. In addition, the governments of several nations subsidize research and development projects to develop new therapeutics.
The appetite for the RSV diagnostics market is driven by factors such as the increased frequency of chronic diseases, such as respiratory disorders, in the neonatal population, the rising number of new newborns, and parental awareness raised by various health organizations. During the projected period, the respiratory syncytial virus (RSV) diagnostic market is anticipated to expand due to the rising need for point-of-care testing to diagnose RSV-infected individuals and developments in the field of markers such as proteomics and genomics. Furthermore, the market for respiratory syncytial virus (RSV) diagnostics is anticipated to grow due to the increased prevalence of RSV infections.
April 2024: Simple HealthKit, a company that enhances healthcare accessibility by providing lab-quality at-home sample collection kits and a full-stack platform for diagnostics, care, and treatment, has announced the availability of its at-home diagnostics and follow-up care kits for Diabetes (HbA1c), Respiratory Wellness, and Sexual Wellness on Amazon.com. The only products in Amazon's U.S. store that cover Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) are the company's at-home Respiratory Wellness tests. Simple HealthKit's at-home diagnostics and programs are intended to assist individuals in the early detection of emergent health conditions, prior to their development into chronic or acute conditions. As such, they are both affordable and accessible. The end-to-end healthcare infrastructure has been constructed by Simple HealthKit, which includes its own CLIA-certified and CAP-accredited laboratories for testing and follow-up care, as well as connections for treatment. The process commences with the provision of rapid results and reliable diagnostic tests (available at home, in clinics, or at the pharmacy). If a person's test results are anomalous for a health condition, the immediate next steps for consultation and treatment are provided.
AstraZeneca Pharma India Ltd., a science-led biopharmaceutical company, has been granted marketing approval by the Central Drugs Standard Control Organisation (CDSCO) to import and market 'Palivizumab,' a critical preventive therapy for Respiratory Syncytial Virus (RSV), in India. This approval was granted in October 2023. RSV is the second most common cause of death in infants under one year of age, and it poses a significant global public health challenge, particularly afflicting children. Malaria is the most common cause of death in this age group. 'Palivizumab,' an innovative therapy, is intended to prevent severe lower respiratory tract diseases that necessitate hospitalization due to RSV infection in children at high risk. Children under the age of two who have received treatment for bronchopulmonary dysplasia (BPD) within the past six months, infants born at 35 weeks of gestation or less and under six months of age at the onset of the RSV season, and children under the age of two with significant congenital heart disease (CHD) are all included in these high-risk groups.
The global RSV diagnostics market is segmented on the basis of the product, method, and end-user.
On the basis of product, the market is classified into kits and assays, instruments, and other products.
The global RSV diagnostics market on the basis of the method is segmented into molecular diagnostics, rapid antigen detection test, gel microdroplets, flow cytometry, and others. The rapid antigen detection tests are further classified into enzyme-linked immunosorbent assays, immunofluorescence assays, and other rapid antigen detection tests. The other rapid antigen detection tests are classified into chromatographic immunoassays and optical immunoassays.
News:The National Institutes of Health (NIH) has given Domus Diagnostics, a point-of-care diagnostics firm based in the United States, funding to improve their point-of-care nucleic acid detection and amplification test for simultaneous detection of COVID-19, Flu-A, Flu-B, and RSV. The award will assist in faster validation and expansion of Domus Diagnostics' testing platform for clinical study preparedness. It is worth up to $2.4M and is made possible by the NIH's Rapid Acceleration of Diagnostics (RADx®) Tech program. The Domus Diagnostics platform serves as an ultra-low-cost, zero-power testing framework that will generate revolutionary devices that make it possible to test for infectious diseases at home, in doctors' offices, or public testing facilities in a reliable, accurate, and efficient manner. The gadgets will make infectious illness testing substantially more accessible and affordable worldwide.
On basis of end-user, the market is segmented into hospitals and clinics, clinical laboratories, home care, and others.
Geographically, global RSV diagnostics market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The American RSV diagnostics market is further segmented into North America, and South America. North America is further classified as the US and Canada.
The Europe RSV diagnostics market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and Rest of Western Europe.
The Asia-Pacific RSV diagnostics market is segmented into Japan, China, India, Republic of Korea, Australia, and Rest of Asia-Pacific.
The Middle East & Africa RSV diagnostics market is segmented into the Middle East, and Africa.
Key Players
Quest Diagnostics, Biomerieux, Becton, Dickinson, and Company (BD), Abbott, F. Hoffman-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Biocartis, Luminex, Hologic, Fast Track Diagnostics, Bio-Rad Laboratories Inc., Alere, Inc., Quidel Corporation, others are some prominent players in this market.
Regional Market Summary
Global RSV Diagnostics Market, by Region Market Share, 2017 (%)
Source: MRFR Analysis
The global RSV diagnostics market consists of four regions: the Americas, Europe, Asia-Pacific and the Middle East & Africa. The Americas is expected to dominate the RSV diagnostics market owing to the increasing incidences of RSV, rising healthcare expenditure, and technological developments in molecular diagnostics. For instance, according to the Centers for Disease Control and Prevention, annually in the United States, more than 57,000 children younger than five years old are hospitalized due to RSV infection.
Europe is anticipated to hold the second position in the global RSV diagnostics market. It is expected that the rising automation in vitro diagnostics, increasing occurrence of RSV diseases, and funding provided by the government are anticipated to drive the European market. For instance, according to the data stated by the University of Oxford, it is anticipated that over 30,000 babies and children below five years of age are hospitalized due to RSV in the UK every year.
The Asia-Pacific RSV diagnostics market consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region due to growing infectious disease burden including RSV infection, growing healthcare expenditure, and rising demand for RSV disease diagnosis. Moreover, China, India, and Japan are expected to be the fastest growing markets in the region due to the developing healthcare systems and growing numbers of government initiatives.
The Middle East and Africa is likely to hold the least share in the global RSV diagnostics market. However, growing awareness among the population and high investments by private market players, rising incidences of RSV in children in this region can boost the growth of the market.
Research Methodology
Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, Treatment assessment, competitive landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments & categories geographically presented are studied and are estimated based on primary & secondary research.
The extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the RSV diagnostics market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, & developments related to the market and Treatment Perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases and many others.
Company Profiles
Recent Development
October 2023:Ricoh USA, Inc. has announced the launch of RICOH Remote Patient Monitoring (RPM) Enablement, the company's newest end-to-end managed services offering for health systems. The offering is intended to help fuel more efficient and sustainable RPM workflows, which can lead to better patient and care delivery team experiences.
April 2023:LifeSigns iMS (India), a health-tech startup, has launched a wireless continuum care solution that allows for real-time wireless remote patient monitoring regardless of location. The solution can be used to provide seamless care and improve patient outcomes in ambulances, hospitals, and at home.
January 2023:Senet (US) and Telli Health (US) have announced the release of the first LoRaWAN®-powered remote patient monitoring (RPM) hardware. This technology will enable providers to reach more patients in remote and underserved areas, such as indigenous communities around the world, increasing healthcare equity and inclusivity and laying the groundwork for future smart home services.
October 2022:GE Healthcare and AMC Health have announced a partnership that will enable clinicians to offer Remote Patient Monitoring (RPM) as a virtual care solution that will extend patient care outside of the hospital to the home environment.
August 2022:Medtronic plc (US) has announced a strategic alliance with BioIntelliSense, a multi-parameter wearable for remote patient monitoring. The collaboration allows Medtronic Patient Monitoring to provide access to a medical grade device that provides continuous vital sign measurements of general care patients in-hospital and after discharge.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.96 Billion |
| Market Size 2023 | USD 1.02 Billion |
| Market Size 2032 | USD 2.82 Billion |
| Compound Annual Growth Rate (CAGR) | 19.70% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Method, and End-user |
| Geographies Covered | Americas, Europe, Asia-Pacific and the Middle East & Africa |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Quest Diagnostics, Biomerieux, Becton, Dickinson, and Company (BD), Abbott, F. Hoffman-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Biocartis, Luminex, Hologic, Fast Track Diagnostics, Bio-Rad Laboratories Inc., Alere, Inc., & Quidel Corporation |
| Key Market Opportunities | Rising demand for point-of-care facilities |
RSV Diagnostics Market Highlights:
Frequently Asked Questions (FAQ) :
The global RSV diagnostics market has the chance to score a CAGR of 19.70% during the forecast period covering 2023 to 2022.
Factors like lack of specific treatment options and a high number of other pathogens that can work in similar situations can impact the RSV diagnostics market growth.
The RSV diagnostics market has end users like hospitals & clinics, home care, clinical laboratories, and others.
The US would dominate the American RSV diagnostics market.
The global RSV diagnostics market would be controlled mostly by companies like Biomerieux, Quest Diagnostics, Abbott, F. Hoffman-La Roche Ltd., Becton, Dickinson, and Company (BD), Thermo Fisher Scientific, Danaher Corporation, Luminex, Hologic, Fast Track Diagnostics, Biocartis, Alere, Inc., Bio-Rad Laboratories Inc., Quidel Corporation, and others.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
